

1 **A prospective study of risk factors associated with seroprevalence of SARS-CoV-2 antibodies in**  
2 **healthcare workers at a large UK teaching hospital**

3

4 Daniel J Cooper<sup>1,2\*</sup>, Sara Lear<sup>1</sup>, Laura Watson<sup>3</sup>, Ashley Shaw<sup>1</sup>, Mark Ferris<sup>1</sup>, Rainer Doffinger<sup>1</sup>, Rachel  
5 Bousfield<sup>1</sup>, Katherine Sharrocks<sup>1</sup>, Michael P. Weekes<sup>1</sup>, Ben Warne<sup>1</sup>, Dominic Sparkes<sup>1,4</sup>, Nick K Jones<sup>1,4</sup>, Lucy  
6 Rivett<sup>1,4</sup>, Matthew Routledge<sup>1,4</sup>, Afzal Chaudhry<sup>1</sup>, Katherine Dempsey<sup>3</sup>, Montgomery Matson<sup>5</sup>, Adil Lakha<sup>5</sup>,  
7 George Gathercole<sup>5</sup>, Olivia O'Connor<sup>5</sup>, Emily Wilson<sup>5</sup>, Orthi Shahzad<sup>5</sup>, Kieran Toms<sup>5</sup>, Rachel Thompson<sup>5</sup>, Ian  
8 Halsall<sup>1</sup>, David Halsall<sup>1</sup>, Sally Houghton<sup>1</sup>, Sofia Papadia<sup>6,7</sup>, Nathalie Kingston<sup>6,8</sup>, Kathleen E Stirrups<sup>6,8</sup>, Barbara  
9 Graves<sup>6,7</sup>, Neil Walker<sup>6,8</sup>, Hannah Stark<sup>6,7</sup>, the CITIID-NIHR BioResource COVID-19 Collaboration, Daniela  
10 De Angelis<sup>9</sup>, Shaun Seaman<sup>9</sup>, John R Bradley<sup>1,6</sup>, M. Estée Török<sup>1,10</sup>, Ian Goodfellow<sup>11†</sup>, Stephen Baker<sup>10,12†</sup>

11

12 <sup>1.</sup> Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

13 <sup>2.</sup> Global and Tropical Health Division, Menzies School of Health Research and Charles Darwin  
14 University, Darwin, Northern Territory, Australia.

15 <sup>3.</sup> NIHR Cambridge Clinical Research Facility.

16 <sup>4.</sup> Clinical Microbiology and Public Health Laboratory, Public Health England, United Kingdom

17 <sup>5.</sup> University of Cambridge School of Clinical Medicine, Cambridge, UK.

18 <sup>6.</sup> NIHR BioResource, NIHR Cambridge Biomedical Research Centre, Cambridge Biomedical Campus,  
19 Cambridge, UK

20 <sup>7.</sup> Department of Public Health and Primary Care, School of Clinical Medicine, University of Cambridge,  
21 Cambridge Biomedical Campus, Cambridge, UK

22 <sup>8.</sup> Department of Haematology, School of Medicine, University of Cambridge, Cambridge Biomedical  
23 Campus, Cambridge, UK.

24 <sup>9.</sup> MRC Biostatistics Unit, University of Cambridge, Cambridge, UK.

25 <sup>10.</sup> Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge  
26 Biomedical Campus, Cambridge, UK.

27 <sup>11.</sup> Department of pathology, Division of virology, University of Cambridge, Cambridge Biomedical  
28 Campus, Cambridge, UK.

29 <sup>12.</sup> Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge  
30 School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK.

31 † Senior authors

32 \*corresponding author: Dr Daniel J Cooper

33

34 **Running title**

35 SARS-CoV-2 sero-epidemiology

36

37 **Key words**

38 SARS-CoV-2; COVID-19; sero-epidemiology; healthcare workers; risk factor analysis

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59 **Abstract**

60 *Background*

61 The COVID-19 pandemic continues to grow at an unprecedented rate. Healthcare workers (HCWs)  
62 are at higher risk of SARS-CoV-2 infection than the general population but risk factors for HCW  
63 infection are not well described.

64 *Methods*

65 We conducted a prospective sero-epidemiological study of HCWs at a UK teaching hospital using a  
66 SARS-CoV-2 immunoassay. Risk factors for seropositivity were analysed using multivariate logistic  
67 regression.

68 *Findings*

69 410/5,698 (7.2%) staff tested positive for SARS-CoV-2 antibodies. Seroprevalence was higher in  
70 those working in designated COVID-19 areas compared with other areas (9.47% versus 6.16%)  
71 Healthcare assistants (aOR 2.06 [95%CI 1.14-3.71];  $p=0.016$ ) and domestic and portering staff (aOR  
72 3.45 [95% CI 1.07-11.42];  $p=0.039$ ) had significantly higher seroprevalence than other staff groups  
73 after adjusting for age, sex, ethnicity and COVID-19 working location. Staff working in acute  
74 medicine and medical sub-specialities were also at higher risk (aOR 2.07 [95% CI 1.31-3.25];  
75  $p<0.002$ ). Staff from Black, Asian and minority ethnic (BAME) backgrounds had an aOR of 1.65  
76 (95% CI 1.32 – 2.07;  $p<0.001$ ) compared to white staff; this increased risk was independent of  
77 COVID-19 area working. The only symptoms significantly associated with seropositivity in a  
78 multivariable model were loss of sense of taste or smell, fever and myalgia; 31% of staff testing  
79 positive reported no prior symptoms.

80 *Interpretation*

81 Risk of SARS-CoV-2 infection amongst HCWs is heterogeneous and influenced by COVID-19  
82 working location, role, age and ethnicity. Increased risk amongst BAME staff cannot be accounted for  
83 solely by occupational factors.

84 *Funding*

85 Wellcome Trust, Addenbrookes Charitable Trust, National Institute for Health Research, Academy of  
86 Medical Sciences, the Health Foundation and the NIHR Cambridge Biomedical Research Centre.

87

## 88 **Research in context**

### 89 *Evidence before this study*

90 Specific risk factors for SARS-CoV-2 infection in healthcare workers (HCWs) are not well defined.  
91 Additionally, it is not clear how population level risk factors influence occupational risk in defined  
92 demographic groups. Only by identifying these factors can we mitigate and reduce the risk of  
93 occupational SARS-CoV-2 infection. We performed a review of the evidence for HCW-specific risk  
94 factors for SARS-CoV-2 infection. We searched PubMed with the terms “SARS-CoV-2” OR  
95 “COVID-19” AND “Healthcare worker” OR “Healthcare Personnel” AND “Risk factor” to identify  
96 any studies published in any language between December 2019 and September 2020. The search  
97 identified 266 studies and included a meta-analysis and two observational studies assessing HCW  
98 cohort seroprevalence data. Seroprevalence and risk factors for HCW infections varied between  
99 studies, with contradictory findings. In the two serological studies, one identified a significant  
100 increased risk of seroprevalence in those working with COVID-19 patients (Eyre *et al* 2020), as well  
101 as associations with job role and department. The other study (Dimcheff *et al* 2020) found no  
102 significant association between seropositivity and any identified demographic or occupational factor.  
103 A meta-analysis of HCW (Gomez-Ochoa *et al* 2020) assessed >230,000 participants as a pooled  
104 analysis, including diagnoses by both RT-PCR and seropositivity for SARS-CoV-2 antibodies and  
105 found great heterogeneity in study design and reported contradictory findings. Of note, they report a  
106 seropositivity rate of 7% across all studies reporting SARS-CoV-2 antibodies in HCWs. Nurses were  
107 the most frequently affected healthcare personnel and staff working in non-emergency inpatient  
108 settings were the most frequently affected group. Our search found no prospective studies  
109 systematically evaluating HCW specific risk factors based entirely on seroprevalence data.

110

### 111 *Added value of this study*

112 Our prospective cohort study of almost 6,000 HCWs at a large UK teaching hospital strengthens  
113 previous findings from UK-based cohorts in identifying an increased risk of SARS-CoV-2 exposure  
114 amongst HCWs. Specifically, factors associated with SARS-CoV-2 exposure include caring for

115 confirmed COVID-19 cases and identifying as being within specific ethnic groups (BAME staff). We  
116 further delineated the risk amongst BAME staff and demonstrate that occupational factors alone do  
117 not account for all of the increased risk amongst this group. We demonstrate for the first time that  
118 healthcare assistants represent a key at-risk occupational group, and challenge previous findings of  
119 significantly higher risk amongst nursing staff. Seroprevalence in staff not working in areas with  
120 confirmed COVID-19 patients was only marginally higher than that of the general population within  
121 the same geographical region. This observation could suggest the increased risk amongst HCWs  
122 arises through occupational exposure to confirmed cases and could account for the overall higher  
123 seroprevalence in HCWs, rather than purely the presence of staff in healthcare facilities.  
124 Over 30% of seropositive staff had not reported symptoms consistent with COVID-19, and in those  
125 who did report symptoms, differentiating COVID-19 from other causes based on symptom data alone  
126 was unreliable.

127

#### 128 *Implications of all the available evidence*

129 International efforts to reduce the risk of SARS-CoV-2 infection amongst HCWs need to be  
130 prioritised. The risk of SARS-CoV-2 infection amongst HCWs is heterogenous but also follows  
131 demonstrable patterns. Potential mechanisms to reduce the risk for staff working in areas with  
132 confirmed COVID-19 patients include improved training in hand hygiene and personal protective  
133 equipment (PPE), better access to high quality PPE, and frequent asymptomatic testing. Wider  
134 asymptomatic testing in healthcare facilities has the potential to reduce spread of SARS-CoV-2 within  
135 hospitals, thereby reducing patient and staff risk and limiting spread between hospitals and into the  
136 wider community. The increased risk of COVID-19 amongst BAME staff cannot be explained by  
137 purely occupational factors; however, the increased risk amongst minority ethnic groups identified  
138 here was stark and necessitates further evaluation.

139

140

141

142

143

## 144 **Background**

145 With >30 million cases and >1 million deaths reported to date globally, the ongoing COVID-19  
146 pandemic continues to impact daily life<sup>1</sup>. A nationwide lockdown in the UK on 23<sup>rd</sup> March 2020  
147 succeeded in slowing infection rates<sup>2</sup>; however, a rising number of infections are now being observed  
148 with the easing of lockdown measures<sup>3</sup>. The logistics of managing patients with COVID-19 presented  
149 unique challenges to hospitals and NHS trusts across the UK; evidence and practices evolved rapidly  
150 as experience was gained. Healthcare workers (HCWs) are at a higher risk of SARS-CoV-2 infection  
151 than the general population<sup>4,5</sup>, and some contradictory evidence is emerging for risk factors associated  
152 with SARS-CoV-2 infection in front-line HCWs<sup>6-8</sup>. Protecting HCWs by identifying risk factors for  
153 SARS-CoV-2 infection as the UK continues to see an increase in COVID-19 diagnoses is paramount<sup>3</sup>.  
154 Controlling transmission within a hospital setting, as well as from hospitals back into the community,  
155 is key for controlling the pandemic<sup>9,10</sup>. However, defining HCW specific risk-factors remains a  
156 challenge. Additionally, higher rates of symptomatic SARS-CoV-2 infection, hospitalisation and  
157 death have been observed amongst patients from ethnic minority populations in the UK<sup>11</sup> and  
158 worldwide<sup>12,13</sup>; the reasons for this disparity are unclear. Reported infections in HCW suggests higher  
159 mortality in HCWs from minority backgrounds<sup>14</sup>; however, it is not yet clear to what extent workplace  
160 exposures influence infection. Here, we present the results of a large sero-epidemiological study of  
161 SARS-CoV-2 seropositivity in staff at a teaching hospital in the East of England.

162

## 163 **Methods**

### 164 *Setting*

165 Cambridge University Hospitals NHS Foundation Trust (CUH) is a tertiary referral centre and  
166 teaching hospital with 1,000 beds and 11,545 staff serving a population of 580,000 people in the East  
167 of England. The facility is equipped with a 20-bed ICU, a 23-bed neurosciences and trauma ICU, and  
168 an Emergency Department that receives ~14,000 attendees a month. Between March and June 2020,  
169 CUH treated 525 patients with PCR-confirmed COVID-19 (**Figure 1**). The peak of COVID-19  
170 admissions occurred in late March and early April 2020, with comparatively few COVID-19

171 admissions from June 2020 onwards. The definition of COVID-19 working for the purpose of risk  
172 stratification included clinical areas designated as either “Red” (patients with PCR-confirmed SARS-  
173 CoV-2 infection) or “Amber” (patients for whom there is a high clinical suspicion of COVID-19).  
174  
175 As of September 2020, the East of England reported 27,516 laboratory-confirmed cases of SARS-  
176 CoV-2 infection<sup>15</sup>, with a corresponding population rate of 441.2 per 100,000 people to date. This rate  
177 is substantially less than the worst affected regions of North West England (772.9/100,000) and  
178 Yorkshire and the Humber (693.2/100,000)<sup>15</sup>. According to the 2011 England and Wales census<sup>16</sup>  
179 85.3% of the population of the East of England are White British, 5.5% are White Other, 4.8% are  
180 Asian, 2% are Black, and 1.9% are of Mixed ethnicity. The proportion of Black, Asian, and Minority  
181 Ethnic (BAME) staff employed at CUH is representative of the overall NHS workforce<sup>17</sup> (21.2% vs  
182 20.7%, respectively).  
183  
184 An asymptomatic staff screening programme using SARS-CoV-2 PCR testing was established in  
185 April 2020<sup>18</sup>. A staff screening programme for SARS-CoV-2 serological testing was commenced on  
186 the 10<sup>th</sup> June 2020. All staff members were invited by email to participate in the serological screening  
187 programme and asked to self-refer for a clinic appointment. Written informed consent was obtained  
188 from all participants. As part of this process all participants were invited to join the NIHR  
189 BioResource – COVID-19 Research Cohort (IRAS 220277). At enrolment, participants completed a  
190 questionnaire asking about demographic characteristics, healthcare role, ethnicity, previous symptoms  
191 consistent with COVID-19 and previous results of SARS-CoV-2 PCR testing. A total of 7.8 ml of  
192 blood was collected, including one serum sample and one whole blood sample. The serum sample was  
193 assayed for total SARS-CoV-2 antibody; both residual serum and whole blood were stored for future  
194 analyses.  
195  
196 *Laboratory assays*  
197 Serological testing for antibodies directed against SARS-CoV-2 was performed using the Centaur XP  
198 SARS-Cov-2 Total Antibody assay (Siemens Healthcare Limited, Surrey, UK). This method is a fully

199 automated high throughput enzyme linked chemiluminescent bridging immunoassay which targets the  
200 S1RBD antigen of SARS-CoV-2 and can detect all Ig subclasses (IgG, IgM, and IgA). The quantity  
201 of SARS-CoV2 antibodies correlates directly with relative light units (RLU), which is converted to  
202 Index Values with a measuring interval of 0.05 ->10 index, where values below 1 are reported as  
203 nonreactive and those  $\geq 1.0$  are reported as reactive, as validated by the manufacturer by clinical  
204 correlation. The method was independently validated by Public Health England and has a reported  
205 sensitivity and specificity of 98.1% (95% CI 96.6 – 99.1) and 99.9% (95% CI 99.4 – 100)<sup>19</sup>  
206 respectively. Samples were processed in the Biochemistry laboratory at CUH following the SOP as  
207 stated by the manufacturer in their Instruction for Use (IFU) after a local verification using guidance  
208 from The Royal College of Pathologists<sup>20</sup>.

209

210 As previously described, the RT-PCR assay used at CUH designates a cycle threshold (Ct) of  $\leq 36$  to  
211 correspond to a positive result<sup>18</sup>.

212

### 213 *Statistical analysis*

214 Seroprevalence is reported as a percentage ([proportion with antibodies/number tested] x 100).

215 Logistic regression was used for univariable and multivariable analyses of seroprevalence

216 comparisons. The Wilcoxon rank-sum test was used for comparison of median Ct values. Data were

217 analysed using Stata v14.2 (StataCorp, College Station, Texas).

218

### 219 *Ethical approval*

220 Ethical approval for this study was granted by the East of England – Cambridge Central Research

221 Ethics Committee (IRAS ID: 220277).

222

223

## 224 **Findings**

### 225 *Baseline information*



226 The CUH staff serology screening clinic was operational between 10<sup>th</sup> June and 7 August 2020. A  
227 total of 8,376 (73%) staff attended the clinic for SARS-CoV-2 serology; 5,697/8,376 (68%) of these  
228 consented to be enrolled in the study (Figure 2). 1,700/5,967 (28.5%) of study participants reported  
229 that they had worked in a designated COVID-19 area within the CUH structure during the peak of the  
230 epidemic between February and June 2020. The median age of participants was 38 years (range 17-83  
231 years) and 22.7% (1,293/5,697) were male (Table 1). A total of 22 staff required hospital admission  
232 for COVID-19. No CUH staff members died.

233

234

### 235 *Seroprevalence*

236 The overall seroprevalence of total SARS-CoV-2 antibodies amongst all staff in this study was 7.2%  
237 (410/5,698). Amongst those reporting having worked in a dedicated COVID-19 area between  
238 February and June 2020, the seroprevalence increased to 9.5% (169/1,784; Table 2). Conversely, the  
239 comparable seroprevalence in those reporting they had never worked in COVID-19 area was 6.2%  
240 (241/3,913;  $p<0.0001$ ). The prevalence of seropositivity in male staff (8.0%; 104/1293) was not  
241 significantly different ( $p=0.18$ ) than that observed in female staff (6.95%; 306/4404). The risk of  
242 seropositivity decreased with age, with an odds ratio (OR) of 0.83 (95% CI 0.76 – 0.91) for every 10-  
243 year increase in age ( $p<0.0001$ ).

244

### 245 *Occupation*

246 On univariate analysis, a number of HCW roles were associated with greater risk of the detection of  
247 SARS-CoV-2 antibodies. Nursing staff (OR 1.68 [95% CI 1.04 – 2.71];  $p=0.033$ ), healthcare  
248 assistants (HCAs) (OR 2.63 [95% CI 1.48 – 4.86];  $p=0.001$ ) physiotherapists (OR 2.48 [95% CI 1.08  
249 – 5.69];  $p=0.032$ ) and porters and domestic staff (OR 3.60 [95% CI 1.13 – 11.44];  $p=0.03$ ) all  
250 displayed a higher risk compared to administrative staff (Table 2), who had the lowest seroprevalence  
251 at 4.6% (19/412). Security staff at CUH are employed by a third-party contractor and did not attend  
252 the staff serology testing clinic.

253

254 *Division/department*

255 Staff departments at CUH are separated into six “Divisions” (Table 3). Risk differed significantly by  
256 division ( $p$  value for the likelihood ratio test of the overall effect of division  $<0.001$ ). Staff working  
257 within Division C (primarily acute medicine, medical sub-specialities and Emergency Department)  
258 had a significantly higher seroprevalence (OR 2.8 [95% CI 1.82 – 4.33]  $p<0.0001$ ) compared to staff  
259 working in Division E (paediatrics and maternity), who had the lowest seroprevalence (5.0%; 38/741).  
260 Staff working specifically in the ICUs had a seroprevalence of 6.33% (10/158), and staff working  
261 specifically in the Emergency Department had a seroprevalence of 9.1% (9/99). However, neither of  
262 these staff groups had significantly different seropositivity using univariate analysis ( $p>0.1$  in both  
263 groups) compared to non-ICU and non-Emergency Department staff respectively.

264

265 *Ethnicity*

266 We observed substantial heterogeneity in the proportion of seropositivity between self-reported ethnic  
267 groups (Table 2). Staff identifying as White had an overall seropositivity rate of 6.1%. In comparison,  
268 Asian staff (Indian/Pakistani/Bangladeshi/Other Asian) and Black staff (Black African/Black  
269 Caribbean/Other black) had a seroprevalence of 11.0% (85/771) and 18.3% (22/120), respectively.  
270 White staff were more likely to have reported symptoms than Asian or Black staff (29%, 28% and  
271 19% respectively). Despite this, seroconversion following symptoms consistent with COVID-19 was  
272 significantly higher in Black staff ( $p=0.002$ ) and in Asian staff ( $p<0.001$ ) compared to white staff;  
273 41% (9/22), 26.6% (54/203), and 14.1% (148/1052) of staff had SARS-CoV-2 antibodies after  
274 reporting consistent symptoms in Black, Asian and White staff, respectively. The proportion of staff  
275 reporting having worked in a COVID-19 area was 38.5%, 60.3% and 32.1% for Black, Asian and  
276 White staff, respectively.

277

278 *Multivariable analyses*

279 After describing several variables associated with SARS-CoV-2 seropositivity in a univariate analysis  
280 we included these variables to assess the risk associated with age, sex, ethnicity, job role and COVID-  
281 working status in a multivariable model. Increasing age remained protective for seropositivity on

282 multivariable analysis (aOR 0.85 per 10 years increase in age [95% CI 0.78 – 0.93];  $p < 0.001$ ). The  
283 aOR of having detectable SARS-CoV-2 antibodies in those that reported working in COVID-19 areas  
284 was 1.50 (95% CI 1.22 – 1.84;  $p < 0.0001$ ). Nursing staff and physiotherapists were no longer  
285 significantly associated with seropositivity on multivariable analysis (Table 2, Figure 3). HCAs  
286 remained at a significantly higher risk of being seropositive (aOR 2.06 [95% CI 1.14 – 3.71 – 2.4];  
287  $p = 0.016$ ), as were domestic and portering staff (aOR 3.45 [95% CI 1.07 – 11.2];  $p = 0.039$ ). In a  
288 separate multivariable model including Division (Table 4), staff working in Division C (acute  
289 medicine, medical sub-specialities and Emergency Department) had an aOR of 2.07 (95% CI 1.31 –  
290 3.25) for seropositivity ( $p = 0.002$ ) after controlling for age, sex, ethnicity, job role and COVID-19 area  
291 working.

292

293 Ethnicity remained strongly associated with seropositivity (Table 2, Figure 4). The aORs in Asian and  
294 black staff in the multivariable model were 1.69 (95% CI 1.30 – 2.19;  $p < 0.0001$ ) and 3.42 (95% CI  
295 2.12 – 5.53;  $p < 0.0001$ ), respectively (Table 2). There was no significant evidence that the effect of  
296 ethnicity was modified by COVID working location ( $p$  value of interaction 0.96), and we also  
297 observed a similar increase in risk associated with ethnicity when data were stratified by CUH  
298 COVID-19 working location. For Asian staff, the aOR for seroconversion was 1.59 (95% CI 1.09 –  
299 2.32;  $p = 0.016$ ) for those working in COVID-19 areas compared to 1.76 (95% CI 1.21 – 2.55;  
300  $p = 0.003$ ) for those not working in COVID-19 areas. For black staff the aOR for seroconversion when  
301 working in COVID-19 areas was 3.91 (95% CI 1.78 – 8.59;  $p = 0.001$ ), compared to 3.06 (95% CI 1.65  
302 – 5.64;  $p < 0.001$ ) who reported working in a non-COVID-19 area.

303

304 The aOR for seropositivity in staff self-reporting as BAME (as a binary variable compared to white  
305 staff in a separate multivariable model) was 1.65 (95% CI 1.32 – 2.07;  $p < 0.0001$ ) after controlling for  
306 age, sex, job role and COVID-19 working location. For staff self-reporting as BAME, the aOR for  
307 seroconversion was 1.59 (95% CI 1.13 – 2.23;  $p = 0.007$ ) for those working in COVID-19 areas and  
308 1.68 (95% CI 1.23 – 2.39;  $p = 0.001$ ) for those who reported not working in a COVID-19 area during  
309 the epidemic.

310

### 311 *Symptoms*

312 Participants were asked about any symptoms consistent with COVID-19 since February 2020.  
313 Critically, seroprevalence was significantly higher in the group with symptoms (17.2%; 266/1,548) in  
314 comparison to those without symptoms (3.1%; 117/3827,  $p<0.0001$ ). Almost 31% (126/410) of  
315 seropositive HCWs reported not having any symptoms consistent with COVID-19 since February  
316 2020. After adjusting for age, sex and ethnicity, the aOR of seropositivity was 6.97 (95% CI 5.54 –  
317 8.78;  $p<0.0001$ ) in the group who reported prior symptoms compared to those who did not. The loss  
318 of the sense of taste or smell was the strongest predictor of seropositivity on univariate analysis;  
319 however, only 44% (154/351) of those reporting the loss of taste or smell were seropositive (Table 5).  
320 In a multivariable logistic regression model containing all collected symptoms (Table 5), loss of sense  
321 of taste or smell (aOR 7.85 [95% CI 5.79 – 10.65],  $p<0.0001$ ), myalgia (aOR 1.71 [95% CI 1.18 –  
322 2.48],  $p<0.0005$ ) and fever (aOR 1.44 [95% CI 1.02 – 2.04],  $p<0.038$ ) were the only symptoms  
323 positively associated with seropositivity. Notably, reporting a sore throat at the time of symptoms was  
324 negatively associated with seropositivity (aOR 0.7 [95% CI 0.50 – 0.99],  $p=0.043$ ) in the  
325 multivariable model.

326

### 327 *Seroconversion after positive SARS-CoV-2 PCR*

328 From 5,991 enrolled participants, 2,825 (47%) reported having had a SARS-CoV-2 PCR test between  
329 February 2020 and the time of blood sampling, primarily through the CUH HCW testing programme.  
330 Of these, 51 (2.05%) tested PCR positive for SARS-CoV-2 RNA, 47 had detectable SARS-CoV-2  
331 antibodies, and four had no detectable SARS-CoV-2 antibodies. The median SARS-CoV-2 PCR Ct  
332 value in those who seroconverted was 30 (IQR 24 – 34), in comparison to 36 (IQR 35.5 – 37) in those  
333 who did not seroconvert ( $p=0.006$ ). The four staff who had previously tested SARS-CoV-2 PCR  
334 positive and were antibody negative all reported having symptoms consistent with COVID-19  
335 infection at the time of PCR testing, although none reported the loss of taste or smell. Nine (18%) of  
336 the staff previously testing SARS-CoV-2 PCR positive, and who were antibody positive, were  
337 asymptomatic at the time of PCR testing.

338

### 339 **Interpretation**

340 In this comprehensive assessment of factors associated with seropositivity for SARS-CoV-2  
341 antibodies in HCWs at a large UK tertiary referral centre we were able to identify key at-risk  
342 occupational groups. Specifically, staff working in areas where patients with confirmed SARS-CoV-2  
343 infection are cared for, those employed as HCA or domestic and portering staff, those of younger age,  
344 and those working in acute medicine or a medical sub-speciality were more likely to have SARS-  
345 CoV-2 antibodies. A reduced risk of SARS-CoV-2 seropositivity was associated with White ethnicity,  
346 being employed in an administrative role or working in paediatric or maternity services, and  
347 belonging to an older age group.

348

349 We found that the seroprevalence of SARS-CoV-2 antibodies in staff working in non-COVID facing  
350 areas was slightly higher (6.16%) than in the general population in the East of England (5.0%)<sup>21</sup> and  
351 comparable to the national prevalence (6.0%)<sup>21</sup>. This is in keeping with previous retrospective  
352 serological HCW studies reporting relatively low seroprevalences in Germany (1.6%)<sup>22</sup>, Wuhan  
353 (3.8%)<sup>23</sup> and Belgium (7.6%)<sup>24</sup>. Amongst Asian staff working at CUH the seroprevalence was also  
354 comparable to East of England data (10.5% vs 10.1%, respectively), as was the seroprevalence  
355 amongst Black staff at CUH compared to regional data (18% vs 15%, respectively)<sup>21</sup>. Overall, we  
356 observed significantly higher seroprevalence in all BAME staff compared to White staff, and to a  
357 greater extent in Black and Asian staff specifically. These differences have been observed nationally  
358 and are not unique to HCWs. The finding that the increased risk associated with BAME staff was not  
359 influenced by COVID-19 area working, as well as the ethnic differences in symptomatic  
360 seroconversion rates, demonstrates that the increased prevalence of antibodies in BAME HCWs  
361 cannot be accounted for by purely occupational factors.

362

363 In staff who were previously SARS-CoV-2 PCR positive, 92% (47/51) had detectable antibodies.  
364 There was a significant difference in Ct values between those who did and did not seroconvert. A  
365 potential explanation for this difference is that higher viral loads may be required to generate a

366 sustained antibody response. Alternatively, a false positive SARS-CoV-2 PCR result or the detection  
367 of viral nucleic acid without infectious virus would also explain a lack of seroconversion.

368

369 Consistent with previous studies, we demonstrate that whilst reporting prior symptoms consistent with  
370 COVID-19 increased the chances of seropositivity, differentiating previous COVID-19 infection from  
371 other common respiratory tract infections based on symptoms alone is unreliable<sup>6</sup>. Interestingly, the  
372 only symptoms that significantly predicted seropositivity on a multivariable logistic regression model  
373 were the loss of sense of taste or smell, myalgia and fever. Prior reporting of cough or shortness of  
374 breath were not good predictors of the presence of SARS-CoV-2 antibodies in a multivariable model.  
375 These data also reiterate previous findings that asymptomatic SARS-COV-2 infection amongst  
376 healthcare workers is common, with 31% of seropositive staff having never reported consistent  
377 symptoms, and 18% of PCR positive staff never having reported consistent symptoms. These data  
378 highlight the importance of the contribution of the asymptotically infected population to the spread  
379 of the disease<sup>25,26</sup>. Consequently, asymptomatic screening of staff in healthcare settings should  
380 become a component of routine disease surveillance<sup>6,18,27</sup>.

381

382 We acknowledge several limitations to our study. Variables such as ethnicity, COVID-working  
383 location and job role were self-reported; however, we have no reason to think these variables were  
384 party to recall bias and it is unlikely to impact on the results to any large degree. The proportion of  
385 staff reporting being of Black ethnicity was relatively small, although the proportion of BAME staff is  
386 consistent with the wider NHS workforce, and our conclusions are therefore broadly generalisable.  
387 The terminology and designation of COVID-facing clinical areas was an evolving factor throughout  
388 the course of the epidemic and is likely to be variable between hospital trusts and regions, as will the  
389 re-distribution of workforces and workflows through hospitals. Additionally, there will be  
390 heterogeneity of infection rates and admission pressures between different regions and between  
391 different hospitals within the same regions that may influence HCW exposure to infection differently.  
392 Consequently, this variation between practices may impact the specific risk factors assessed in this  
393 study to varying extents between different healthcare trusts. We were also unable to assess the use of

394 PPE and adherence to PPE protocols in this study design. The selected assay may have reduced  
395 sensitivity in individuals who generated robust antibody responses to other SARS-COV-2 antigens or  
396 those producing low affinity antibodies during early disease. Similar considerations apply to other  
397 commercial assays<sup>28</sup>, and a recent comparison demonstrated assay equivalence with the selected  
398 platform having higher accuracy<sup>19</sup>, and an independently reported sensitivity and specificity of 98.1%  
399 (95% CI 96.6 – 99.1) and 99.1% (95% CI 99.4 – 100) respectively<sup>19</sup>. We also note that symptom data  
400 were recorded retrospectively, and may have been subject to recall bias.

401

402 Our study provides new information on the risk factors for SARS-COV-2 infection and antibody  
403 response in healthcare facilities. We found that the occupational exposure to SARS-COV-2 is  
404 heterogenous across job roles, hospital department, and ethnicity. It is clear that HCWs on the  
405 frontline of the COVID-19 pandemic require more protection from occupational exposure with  
406 accurate stratification of risk factors to develop mitigation strategies. The association with ethnic  
407 group is concerning and a deeper understanding of the societal and/or genetic factors predisposing the  
408 BAME population to SARS-COV-2 infection and seroconversion is needed.

409

#### 410 **Funding**

411 SGB, IGG and MPW are funded by Wellcome Senior Fellowships (Grant ID 215515/Z/19/Z,  
412 207498/Z/17/Z, 108070/Z/15/Z). DJC and SL received funding for this work from Addenbrooke's  
413 Charitable Trust (Grant ID 900254). MET is supported by the Academy of Medical Sciences, the  
414 Health Foundation and the NIHR Cambridge Biomedical Research Centre. BW is funded by the  
415 National Institute for Health Research Cambridge Biomedical Research Centre at the Cambridge  
416 University Hospitals NHS Foundation Trust.

417

#### 418 **Acknowledgements**

419 We thank NIHR BioResource volunteers for their participation, and gratefully acknowledge NIHR  
420 BioResource centres, NHS Trusts and staff for their contribution. We thank the National Institute for  
421 Health Research, NHS Blood and Transplant, and Health Data Research UK as part of the Digital

422 Innovation Hub Programme. The views expressed are those of the author(s) and not necessarily those  
423 of the NHS, the NIHR or the Department of Health and Social Care. The authors also thank the  
424 Occupational Health Department at CUH for facilitating sample and data collection during the staff  
425 serology testing clinic.

426

427 *References*

428

429

- 430 1. World Health Organisation. Coronavirus disease (COVID-2019) situation reports.
- 431 2. Anderson RM, Hollingsworth TD, Baggaley RF, Maddren R, Vegvari C. COVID-19 spread  
432 in the UK: the end of the beginning? *Lancet* 2020; **396**(10251): 587-90.
- 433 3. Johns Hopkins University. COVID-19 map. Available at:  
434 <https://coronavirus.jhu.edu/map.html>. Accessed 23rd September 2020. .
- 435 4. Nguyen LH, Drew DA, Joshi AD, et al. Risk of COVID-19 among frontline healthcare  
436 workers and the general community: a prospective cohort study. *medRxiv* 2020.
- 437 5. Gomez-Ochoa SA, Franco OH, Rojas LZ, et al. COVID-19 in Healthcare Workers: A Living  
438 Systematic Review and Meta-analysis of Prevalence, Risk Factors, Clinical Characteristics, and  
439 Outcomes. *Am J Epidemiol* 2020.
- 440 6. Eyre DW, Lumley SF, O'Donnell D, et al. Differential occupational risks to healthcare  
441 workers from SARS-CoV-2 observed during a prospective observational study. *Elife* 2020; **9**.
- 442 7. Shields A, Faustini SE, Perez-Toledo M, et al. SARS-CoV-2 seroprevalence and  
443 asymptomatic viral carriage in healthcare workers: a cross-sectional study. *Thorax* 2020.
- 444 8. Dimcheff DE, Schildhouse RJ, Hausman MS, et al. Seroprevalence of Severe Acute  
445 Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Infection Among VA Healthcare System  
446 Employees Suggests Higher Risk of Infection When Exposed to SARS-CoV-2 Outside of the Work  
447 Environment. *Infect Control Hosp Epidemiol* 2020: 1-25.
- 448 9. The L. COVID-19: protecting health-care workers. *Lancet* 2020; **395**(10228): 922.



- 449 10. Wang J, Zhou M, Liu F. Reasons for healthcare workers becoming infected with novel  
450 coronavirus disease 2019 (COVID-19) in China. *J Hosp Infect* 2020; **105**(1): 100-1.
- 451 11. Sapey E, Gallier S, Mainey C, et al. Ethnicity and risk of death in patients hospitalised for  
452 COVID-19 infection in the UK: an observational cohort study in an urban catchment area. *BMJ Open*  
453 *Respir Res* 2020; **7**(1).
- 454 12. Vahidy FS, Nicolas JC, Meeks JR, et al. Racial and ethnic disparities in SARS-CoV-2  
455 pandemic: analysis of a COVID-19 observational registry for a diverse US metropolitan population.  
456 *BMJ Open* 2020; **10**(8): e039849.
- 457 13. Price-Haywood EG, Burton J, Fort D, Seoane L. Hospitalization and Mortality among Black  
458 Patients and White Patients with Covid-19. *The New England journal of medicine* 2020; **382**(26):  
459 2534-43.
- 460 14. Kursumovic E, Lennane S, Cook TM. Deaths in healthcare workers due to COVID-19: the  
461 need for robust data and analysis. *Anaesthesia* 2020; **75**(8): 989-92.
- 462 15. Gov.uk Coronavirus (COVID-19) in the UK. Cases in United Kingdom. Available at:  
463 <https://coronavirus.data.gov.uk/cases>. Accessed 23rd September 2020. .
- 464 16. Office for National Statistics. 2011 UK census. Available at:  
465 <https://www.ons.gov.uk/census/2011census>. Accessed 23rd September 2020.
- 466 17. Gov.uk. NHS Workforce. Available at: [https://www.ethnicity-facts-](https://www.ethnicity-facts-figures.service.gov.uk/workforce-and-business/workforce-diversity/nhs-workforce/latest)  
467 [figures.service.gov.uk/workforce-and-business/workforce-diversity/nhs-workforce/latest](https://www.ethnicity-facts-figures.service.gov.uk/workforce-and-business/workforce-diversity/nhs-workforce/latest). Accessed  
468 23rd September 2020. .
- 469 18. Rivett L, Sridhar S, Sparkes D, et al. Screening of healthcare workers for SARS-CoV-2  
470 highlights the role of asymptomatic carriage in COVID-19 transmission. *Elife* 2020; **9**.
- 471 19. National S-C-SAEG. Performance characteristics of five immunoassays for SARS-CoV-2: a  
472 head-to-head benchmark comparison. *Lancet Infect Dis* 2020.
- 473 20. Royal College of Pathologists. Verification and validation methodology and sample sets for  
474 evaluation of assays for SARS-CoV-2 (COVID-19). Available here:  
475 [https://www.rcpath.org/uploads/assets/541a4523-6058-4424-81c119dd2ab0febb/Verification-](https://www.rcpath.org/uploads/assets/541a4523-6058-4424-81c119dd2ab0febb/Verification-validation-of-sample-sets-assays-SARS-CoV-2.pdf)  
476 [validation-of-sample-sets-assays-SARS-CoV-2.pdf](https://www.rcpath.org/uploads/assets/541a4523-6058-4424-81c119dd2ab0febb/Verification-validation-of-sample-sets-assays-SARS-CoV-2.pdf). Accessed 23rd September 2020. .

- 477 21. Ward H, Atchison CJ, Whitaker M, et al. Antibody prevalence for SARS-CoV-2 in England  
478 following first peak of the pandemic: REACT2 study in 100,000 adults. *medRxiv* 2020:  
479 2020.08.12.20173690.
- 480 22. Korth J, Wilde B, Dolff S, et al. SARS-CoV-2-specific antibody detection in healthcare  
481 workers in Germany with direct contact to COVID-19 patients. *J Clin Virol* 2020; **128**: 104437.
- 482 23. Xu X, Sun J, Nie S, et al. Seroprevalence of immunoglobulin M and G antibodies against  
483 SARS-CoV-2 in China. *Nat Med* 2020; **26**(8): 1193-5.
- 484 24. Steensels D, Oris E, Coninx L, et al. Hospital-Wide SARS-CoV-2 Antibody Screening in  
485 3056 Staff in a Tertiary Center in Belgium. *JAMA* 2020; **324**(2): 195-7.
- 486 25. Oran DP, Topol EJ. Prevalence of Asymptomatic SARS-CoV-2 Infection : A Narrative  
487 Review. *Ann Intern Med* 2020; **173**(5): 362-7.
- 488 26. Yu X, Yang R. COVID-19 transmission through asymptomatic carriers is a challenge to  
489 containment. *Influenza Other Respir Viruses* 2020; **14**(4): 474-5.
- 490 27. Self WH, Tenforde MW, Stubblefield WB, et al. Seroprevalence of SARS-CoV-2 Among  
491 Frontline Health Care Personnel in a Multistate Hospital Network - 13 Academic Medical Centers,  
492 April-June 2020. *MMWR Morb Mortal Wkly Rep* 2020; **69**(35): 1221-6.
- 493 28. Public Health England. Evaluation of sensitivity and specificity of four commercially  
494 available SARS-CoV-2 antibody immunoassays. 2020. Available at:  
495 [https://www.gov.uk/government/publications/covid-19-head-to-head-laboratory-evaluation-of-4-](https://www.gov.uk/government/publications/covid-19-head-to-head-laboratory-evaluation-of-4-commercial-serological-assays)  
496 [commercial-serological-assays](https://www.gov.uk/government/publications/covid-19-head-to-head-laboratory-evaluation-of-4-commercial-serological-assays).

497

498

499

500

501

502

503

504

505

506

507

508

509 *Figure Legends:*

510

511 **Figure 1:** Epidemic curve of COVID-19 admissions at Cambridge University Hospitals NHS Foundation Trust

512

513 **Figure 2:** Study flowchart

514

515 **Figure 3:** Adjusted odds ratio for SARS-CoV-2 seropositivity according to job role


516


517 **Figure 4:** Adjusted odds ratio for SARS-CoV-2 seropositivity according to ethnic group


518


519

Number of COVID-19 diagnoses per week









<b>Baseline variable</b>	<b>Male</b>	<b>Female</b>
<b>n (%)</b>	1,293 (22.7)	4,404 (77.3)
<b>Age (median [IQR])</b>	38 (30 – 49)	38 (29 – 49)
<b>Age bracket</b>		
16 – 24 years	66	360
25 – 34 years	451	1427
35 – 44 years	336	1035
45 – 54 years	250	919
55 – 64 years	166	555
65 – 74 years	21	74
75 + years	3	4
<b>COVID working (n, %)</b>	493 (38.1)	1,291 (29.3)
<b>Ethnicity</b>		
White (n, %)	887 (68.6)	3,580 (81.3)
BAME (all) (n, %)	382 (29.5)	752 (17.1)
Asian (n, %)	276 (21.4)	495 (11.2)



Black (n, %)	30 (2.3)	90 (2.0)
Chinese (n, %)	21 (1.6)	57 (1.3)
Mixed (n, %)	21 (1.6)	47 (1.1)
Other (n, %)	34 (2.6)	63 (1.4)
Not stated (n, %)	24 (1.9)	72 (1.6)

**Table 1:** Baseline demographics

Variable	Seropositivity n (%)	Unadjusted OR (96% CI)	p value	Adjusted OR (95% CI)	p value
No COVID working	241/3913 (6.16)	1	-	1	-
COVID working	169/1784 (9.47)	1.59 (1.30 – 1.96)	<0.001	1.50 (1.22 – 1.84)	<b>&lt;0.001</b>
Female sex		1	-	1	-
Male sex	104/1293 (8.04)	1.17 (0.93 – 1.47)	0.18	1.10 (0.87 – 1.39)	0.43
Age		-	<0.001*	-	<0.001*
Age 16-24	47/456 (10.3)	1	-	1	-
Age 25-34	152/1878 (8.1)	0.77 (0.54 – 1.08)	0.13	0.72 (0.51 – 1.02)	0.069
Age 35-44	102/1371 (7.4)	0.70 (0.49 – 1.0)	0.054	0.69 (0.48 – 0.99)	<b>0.044</b>
Age 45-54	71/1169 (6.1)	0.56 (0.38 – 0.83)	0.003	0.57 (0.38 – 0.83)	<b>0.004</b>
Age 55-64	32/721 (4.4)	0.40 (0.25 – 0.64)	<0.001	0.44 (0.27 – 0.70)	<b>0.001</b>
Age 65-74	6/95 (6.3)	0.59 (0.24 – 1.4)	0.24	0.66 (0.27 – 1.59)	0.34
Age 75+	0/7 (0)	-	-	-	-
Job role		-	0.0042*	-	0.098*
Administrative	19/412 (4.61)	1	-	1	-
Nursing staff	261 / 3471 (7.52)	1.68 (1.04 – 2.71)	0.033	1.52 (0.94 – 2.46)	0.088

Junior doctor	10/118 (8.47)	1.92 (0.87 – 4.24)	0.11	1.43 (0.64 – 3.23)	0.39
Consultant	10/174 (5.75)	1.26 (0.57 – 2.77)	0.56	1.19 (0.53 – 2.68)	0.42
Healthcare assistant	36/319 (11.29)	2.63 (1.48 – 4.68)	0.001	2.06 (1.14 – 3.71)	<b>0.016</b>
Theatre staff	3/24 (12.5)	2.95 (0.81 – 10.78)	0.10	2.40 (0.65 – 8.87)	0.19
Physiotherapist	9/84 (10.71)	2.48 (1.08 – 5.69)	0.032	1.82 (0.78 – 4.24)	0.16
Domestic and porter	4/27 (14.81)	3.60 (1.13 – 11.44)	0.030	3.45 (1.07 – 11.2)	<b>0.039</b>
Other	58/1068 (5.43)	1.19 (0.67 – 2.02)	0.53	1.06 (0.62 – 1.80)	0.85
Ethnicity	-	-	<0.001*	-	<0.001*
White	275/4467 (6.16)	1	-	1	-
Black	22/120 (18.33)	3.42 (2.12 – 5.52)	<0.001	3.42 (2.12 – 5.53)	<b>&lt;0.001</b>
Asian	85/771 (11.02)	1.89 (1.46 – 2.44)	<0.001	1.69 (1.30 – 2.19)	<b>&lt;0.001</b>
Chinese	5/78 (6.41)	1.04 (0.42 – 2.60)	0.93	1.04 (0.42 – 2.60)	0.94
Mixed	2/68 (2.94)	0.46 (0.11 – 1.90)	0.28	0.42 (0.10 – 1.71)	0.23
Other	9/97 (9.28)	1.56 (0.78 – 3.12)	0.21	1.36 (0.68 – 2.74)	0.38
Not stated	12/96 (12.5)	2.18 (1.17 – 4.04)	0.013	2.10 (1.13 – 3.90)	<b>0.019</b>

**Table 2:** Odds ratio (OR) and adjusted odds ratio (aOR) for variables associated with seropositivity

aORs calculated using a multivariable model containing serostatus, age, sex, ethnicity, job role and COVID-working location.

\*p value for the likelihood ratio test for the overall effect of variable

<b>Division</b>	<b>A</b>	<b>B</b>	<b>C</b>	<b>D</b>	<b>E</b>	<b>Corporate</b>
	Critical Care	Blood sciences	Acute medicine	Cardiology	Paediatrics	CEO
	Anaesthetics	Oncology	Elderly care	Endocrine	Gynaecology	CFO
	General surgery	Histopathology	Emergency Dept	Dermatology	Midwifery	COO
	Gastrointestinal Surgery	Haematology	Hepatobiliary surgery	ENT	Obstetrics	Medical Director
	Rheumatology	Pharmacy	Nephrology	Ophthalmology		Chief Nurse
	Gastrointestinal medicine	Outpatients	Infectious diseases	Neurosciences		Estates
	Theatres	Radiology	Respiratory	Plastics		
	Trauma and Orthopaedics	Urology	Transplant	Rehab		
		Therapies		Stroke		
				Vascular surgery		

**Table 3:** CUH departments by division

Variable	Seropositivity n (%)	Unadjusted OR (96% CI)	<i>p</i> value	Adjusted <sup>a</sup> OR (95% CI)	<i>p</i> value
Division		-	<0.001*	-	<b>0.0068*</b>
A	65/808 (8.0)	1.62 (1.07 – 2.45)	<b>0.022</b>	1.16 (0.74- 1.80)	0.52
B	70/1211 (5.8)	1.14 (0.76 – 1.70)	0.54	1.08 (0.71 – 1.66)	0.71
C	55/417 (13.2)	2.81 (1.82 – 4.33)	<b>&lt;0.001</b>	2.07 (1.31 – 3.25)	<b>0.002</b>
D	43/616 (7.0)	1.39 (0.89 – 2.18)	0.15	1.26 (0.80 – 1.99)	0.33
E	38/741 (5.1)	1	-	1	-
Corporate	26/445 (5.8)	1.15 (0.69 – 1.91)	0.60	1.24 (0.73 – 2.12)	0.43

**Table 4:** Odds ration (OR) and adjusted odds ratio (aOR) of seropositivity by Division

<sup>a</sup>Adjusted for age, sex, ethnicity, job role and working location

\**p* value for the likelihood ratio test for the overall effect of variable

Symptom	Number reporting symptoms n, (%)	Antibody positive	Antibody negative	% positive	Univariable		Multivariable	
					OR	<i>p</i> value	OR	<i>p</i> value
Loss of taste or smell	351 (6.2)	154	197	43.9	15.5 (12.2 – 19.9)	<0.001	10.70 (7.80 – 14.70)	<b>&lt;0.001</b>
Myalgia	807 (14.2)	166	641	20.6	4.9 (4.0 – 6.1)	<0.001	1.71 (1.18 – 2.48)	<b>0.005</b>
Fever	740 (13.0)	147	593	19.9	4.4 (3.60 – 5.51)	<0.001	1.44 (1.02 – 2.04)	<b>0.038</b>
Cough	874 (15.3)	154	720	17.6	3.82 (3.10 – 4.73)	<0.001	1.33 (0.93 – 1.90)	0.11
Headache	847 (14.9)	157	690	18.5	4.13 (3.34 – 5.12)	<0.001	1.32 (0.91 – 1.91)	0.14
Nausea/vomiting/diarrhoea	330 (5.8)	60	270	18.2	3.19 (2.36 – 4.30)	<0.001	1.08 (0.73 – 1.58)	0.71
Nasal Discharge	453 (8.0)	72	381	15.9	2.74 (2.08 – 3.61)	<0.001	0.82 (0.57 – 1.17)	0.27
Shortness of breath	494 (8.7)	85	409	17.2	3.12 (2.41 – 4.04)	<0.001	0.76 (0.51 – 1.13)	0.18
Hoarse voice	314 (5.5)	46	268	14.7	2.37 (1.70 – 3.29)	<0.001	0.75 (0.50 – 1.15)	0.19
Wheeze	285 (5.0)	46	239	16.1	2.67 (1.91 – 3.72)	<0.001	0.74 (0.47 – 1.17)	0.20
Sore throat	806 (14.2)	117	689	14.5	2.66 (2.12 – 3.35)	<0.001	0.70 (0.50 – 0.99)	<b>0.043</b>

**Table 5:** Unadjusted odds ratio (OR) and adjusted odds ratio (aOR) of SARS-CoV-2 seropositivity by reported symptoms

